Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 7/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443587 | 0.83 | CYP1A2 (0.54) | CCR1NR3C1CYP17A1CYP1A2PGR | |
| SCHEMBL4572945 | 0.82 | MKNK1 (0.47) | CCR1NR3C1CYP17A1CYP1A2CYP3A4 | |
| SCHEMBL441916 | 0.82 | CCR1 (0.46) | CCR1NR3C1CYP17A1CYP1A2CYP3A4 | |
| SCHEMBL1255335 | 0.78 | CCR1 (0.58) | CCR1NR3C1CYP11B2 | |
| SCHEMBL4573040 | 0.77 | CCR1 (0.45) | CCR1NR3C1CYP17A1CYP1A2CYP3A4 | |
| SCHEMBL29582723 | 0.75 | NR3C1 (0.46) | CCR1NR3C1PGRCYP11B1CYP11B2 | |
| SCHEMBL4172404 | 0.71 | NR3C1 (0.46) | CCR1NR3C1CYP3A4CYP2C9PGR | |
| SCHEMBL25044244 | 0.67 | NOS1 (0.38) | — | |
| SCHEMBL303982 | 0.66 | CYP17A1 (0.56) | CCR1NR3C1CYP17A1CYP1A2CYP3A4 | |
| SCHEMBL32668800 | 0.66 | HTT (0.51) | CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097384-B1 | INDOZALYL SULPHONAMIDE DERIVATIVES USEFUL AS GLUCOCORTICOID MODULATORS | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| CN-101646654-B | Indazolyl sulfonamide derivatives useful as glucocorticoid modulators | ASTRAZENECA AB | 2012-03-28 | — | — | CN | disclosed |
| US-20120065173-A1 | CHEMICAL COMPOUNDS | BERGER MARKUS (DE) | 2012-03-15 | — | — | US | disclosed |
| US-8030340-B2 | Moderators of glucocorticoids receptor; antiinflamamtory agents; chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2011-10-04 | — | — | US | disclosed |
| CN-101646654-A | Indazolyl sulfonamide derivatives useful as glucocorticoid modulators | ASTRAZENECA AB SE | 2010-02-10 | — | — | CN | disclosed |
| US-20080207721-A1 | Chemical compounds | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207721-A1 | Chemical compounds | NR3C1, NR3C2, MC2R | CCR1 261/4885NR3C1 1/4885CYP17A1 30/4885 |
| US-20120065173-A1 | CHEMICAL COMPOUNDS | NR3C1, NR3C2, MC2R | CCR1 263/4885NR3C1 1/4885CYP17A1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.